NGEN News & Analysis
2 articles
Market Mood
NervGen (NGEN) Stock Price Target Cut to $15 Due to Dilution
H.C. Wainwright has reduced the stock price target for NervGen Pharma (NGEN) to $15. This adjustment reflects concerns over share dilution affecting the company's market valuation. Investors may perceive this downward revision as a sign of potential challenges for NervGen in maintaining stock price stability. The decrease in the target price could impact investor confidence and trading volumes going forward.
Read More: NervGen (NGEN) Stock Price Target Cut to $15 Due to Dilution
NervGen (NGEN) prices $60M public offering at $2.50 per share
NervGen Pharma (NGEN) has announced the pricing of its public offering at $2.50 per share, aiming to raise approximately $60 million. This financing will support the company's ongoing clinical development and operational expenses. The share price reflects a specific valuation and may influence investor sentiment and future stock performance. This capital infusion could impact ongoing projects and potential market strategies moving forward.
Read More: NervGen (NGEN) prices $60M public offering at $2.50 per share